Sex-specific modulation of circulating growth differentiation factor-15 in patients with type 2 diabetes and/or obesity.
GDF15
diabetes
obesity
sex
Journal
Endocrine connections
ISSN: 2049-3614
Titre abrégé: Endocr Connect
Pays: England
ID NLM: 101598413
Informations de publication
Date de publication:
01 Jul 2022
01 Jul 2022
Historique:
received:
02
06
2022
accepted:
13
06
2022
pubmed:
15
6
2022
medline:
15
6
2022
entrez:
14
6
2022
Statut:
epublish
Résumé
Growth differentiation factor-15 (GDF15), a key metabolic regulator, is associated with obesity and diabetes in which sex-specific differences have been reported. Thus, we assessed whether GDF15 could be dependent on sex in diabetes and/or obesity groups. We measured serum GDF15 levels by ELISA in eight lean women and men (n = 16), eight women and eight men having obesity (n = 16), eight women and eight men with type 2 diabetes (T2D, n = 16), and seven women and nine men with both diabetes and obesity (n = 16). Estimation of the difference in the means of each group was performed by two-way ANOVA. The interdependence of the different variates was addressed by multivariate analysis. Correlations between GDF15 levels and HOMA-IR, HbA1c, triglycerides, HDL, and LDL were explored by linear regression. Being a woman and having obesity alone or in combination with diabetes decreased GDF15 serum levels (β = -0.47, CI = -0.95, 0.00, P = 0.052; β = -0.45, CI = -0.94, 0.05, P= 0.075). Diabetes independently of metformin treatment and obesity were not predictive of low GDF15 levels (β = 0.10, CI = -0.36, 0.57, P = 0.7). Correlation analysis showed that HOMA-IR (r = 0.45, P = 0.008) and triglycerides (r = 0.41, P = 0.017) were positively correlated and HDL (r = -0.48, P = 0.005) was negatively correlated with GDF15 levels in men. GDF15 level was significantly different between men and women, as well as between the groups. Sex and group interaction revealed that being a woman and having obesity alone or in combination with diabetes decreased GDF15 levels.
Identifiants
pubmed: 35700236
doi: 10.1530/EC-22-0054
pii: EC-22-0054
pmc: PMC9346339
doi:
pii:
Types de publication
Journal Article
Langues
eng
Références
Eur J Hum Genet. 2021 Jan;29(1):154-163
pubmed: 32873964
Eur Heart J. 2009 Oct;30(19):2346-53
pubmed: 19561023
Geriatr Gerontol Int. 2016 Mar;16 Suppl 1:17-29
pubmed: 27018280
Diabetes Care. 2017 Feb;40(2):280-283
pubmed: 27974345
Am J Physiol Endocrinol Metab. 2019 May 1;316(5):E829-E836
pubmed: 30860878
Diabetes Care. 2014 Jan;37 Suppl 1:S81-90
pubmed: 24357215
Mol Cell Endocrinol. 2022 Feb 5;541:111503
pubmed: 34763008
Obes Facts. 2012;5(2):270-6
pubmed: 22647307
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Diabetes Care. 2007 Jan;30(1):89-94
pubmed: 17192339
Eur J Endocrinol. 2009 Sep;161(3):397-404
pubmed: 19515791
Adv Exp Med Biol. 2017;1043:3-8
pubmed: 29224087
Biochim Biophys Acta Gen Subj. 2021 Mar;1865(3):129834
pubmed: 33358864
Lancet. 2011 Feb 12;377(9765):557-67
pubmed: 21295846
J Clin Endocrinol Metab. 2015 Apr;100(4):1396-404
pubmed: 25636052
Nat Rev Endocrinol. 2021 Oct;17(10):592-607
pubmed: 34381196
Exp Gerontol. 2020 Dec;142:111115
pubmed: 33069782
Clin Chem. 2011 Feb;57(2):309-16
pubmed: 21164037
Eur J Endocrinol. 2012 Nov;167(5):671-8
pubmed: 22918303
J Gerontol A Biol Sci Med Sci. 2019 Apr 23;74(5):600-607
pubmed: 29955888
Nutr Metab (Lond). 2010 Apr 23;7:34
pubmed: 20416056
Aging Cell. 2020 Aug;19(8):e13195
pubmed: 32691494
Nutr Metab Cardiovasc Dis. 2019 Apr;29(4):334-342
pubmed: 30718144
Diabetes Metab J. 2014 Dec;38(6):472-9
pubmed: 25541611
Lancet. 2008 May 24;371(9626):1800-9
pubmed: 18502305
Front Immunol. 2020 May 12;11:915
pubmed: 32477368
Eur J Endocrinol. 2010 May;162(5):913-7
pubmed: 20167682
Endocrinology. 2009 Apr;150(4):1688-96
pubmed: 19074584
Nat Metab. 2019 Dec;1(12):1202-1208
pubmed: 32694673
Toxicol Appl Pharmacol. 2017 Oct 1;332:8-14
pubmed: 28734801
Acta Physiol (Oxf). 2021 May;232(1):e13610
pubmed: 33351229